US 11,986,527 B2
Pharmaceutical formulations containing corticosteroids for topical administration
Arturo Angel, Santa Rosa, CA (US); and Gordon Dow, Greenbrae, CA (US)
Assigned to BAUSCH HEALTH IRELAND LIMITED, Dublin (IE)
Filed by BAUSCH HEALTH IRELAND LIMITED, Dublin (IE)
Filed on Oct. 29, 2018, as Appl. No. 16/174,023.
Application 16/174,023 is a division of application No. 15/966,367, filed on Apr. 30, 2018.
Application 15/966,367 is a continuation in part of application No. 14/340,367, filed on Jul. 24, 2014, granted, now 11,213,587.
Application 14/340,367 is a continuation of application No. 13/287,176, filed on Nov. 2, 2011, granted, now 8,809,307, issued on Aug. 19, 2014.
Claims priority of provisional application 61/458,339, filed on Nov. 22, 2010.
Prior Publication US 2019/0083625 A1, Mar. 21, 2019
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/14 (2017.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 9/107 (2006.01); A61K 9/127 (2006.01); A61K 9/14 (2006.01); A61K 31/573 (2006.01); A61K 31/58 (2006.01); A61P 17/06 (2006.01)
CPC A61K 47/14 (2013.01) [A61K 9/0014 (2013.01); A61K 9/06 (2013.01); A61K 9/107 (2013.01); A61K 9/127 (2013.01); A61K 31/573 (2013.01); A61K 31/58 (2013.01); A61P 17/06 (2018.01)] 18 Claims
 
1. A method of treating a dermatological or mucosal disorder or condition, the method comprising topically administering a pharmaceutical composition comprising a corticosteroid to the skin of an individual having the dermatological or mucosal disorder or condition, wherein the pharmaceutical composition comprises:
a liquid oil component comprising one or more monocarboxylic acid esters and/or dicarboxylic acid esters, and mineral oil, light mineral oil, or a combination thereof, and
a corticosteroid at a concentration of about 0.01% to about 0.030% or less, and wherein at least 25% of the corticosteroid is solubilized in the liquid oil component at a temperature of 22° C.+/−2° C.; and
an aqueous component comprising water;
wherein the corticosteroid is selected from the group consisting of clobetasol propionate, betamethasone dipropionate, halobetasol propionate, diflorasone diacetate, desoximetasone, mometasone furoate, betamethasone valerate, halcinonide, budesonide, fluocinonide, and amcinonide; and
wherein the pharmaceutical composition is free of white petrolatum;
wherein the pharmaceutical composition is formulated as a lotion or a cream.